Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Neutrophils are not consistently activated by antineutrophil cytoplasmic antibodies in vitro.

Popat RJ, Robson MG.

Ann Rheum Dis. 2019 May;78(5):709-711. doi: 10.1136/annrheumdis-2018-214405. Epub 2018 Dec 4. No abstract available.

2.

The NF-κB1 is a key regulator of acute but not chronic renal injury.

Fearn A, Situmorang GR, Fox C, Oakley F, Howarth R, Wilson CL, Kiosia A, Robson MG, Mann DA, Moles A, Sheerin NS.

Cell Death Dis. 2017 Jun 15;8(6):e2883. doi: 10.1038/cddis.2017.233.

3.

Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development.

Popat RJ, Hakki S, Thakker A, Coughlan AM, Watson J, Little MA, Spickett CM, Lavender P, Afzali B, Kemper C, Robson MG.

JCI Insight. 2017 Jan 26;2(2):e87379. doi: 10.1172/jci.insight.87379.

4.

Loss of endogenous thymosin β4 accelerates glomerular disease.

Vasilopoulou E, Kolatsi-Joannou M, Lindenmeyer MT, White KE, Robson MG, Cohen CD, Sebire NJ, Riley PR, Winyard PJ, Long DA.

Kidney Int. 2016 Nov;90(5):1056-1070. doi: 10.1016/j.kint.2016.06.032. Epub 2016 Aug 26.

5.

Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5.

Freeley SJ, Popat RJ, Parmar K, Kolev M, Hunt BJ, Stover CM, Schwaeble W, Kemper C, Robson MG.

J Pathol. 2016 Sep;240(1):61-71. doi: 10.1002/path.4754.

6.

Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial.

Karunanithy N, Mesa IR, Dorling A, Calder F, Katsanos K, Semik V, Robinson E, Peacock J, Das N, Forman C, Lawman S, Steiner K, Wilkins CJ, Robson MG.

Trials. 2016 May 12;17(1):241. doi: 10.1186/s13063-016-1372-7.

7.

Complement and glomerular diseases.

Popat RJ, Robson MG.

Nephron Clin Pract. 2014;128(3-4):238-42. doi: 10.1159/000368591. Epub 2014 Nov 19. Review.

8.

Toll-like receptor 2 or toll-like receptor 4 deficiency does not modify lupus in MRLlpr mice.

Freeley SJ, Giorgini A, Tulone C, Popat RJ, Horsfield C, Robson MG.

PLoS One. 2013 Sep 24;8(9):e74112. doi: 10.1371/journal.pone.0074112. eCollection 2013.

9.

Granulocyte colony stimulating factor exacerbates antineutrophil cytoplasmic antibody vasculitis.

Freeley SJ, Coughlan AM, Popat RJ, Dunn-Walters DK, Robson MG.

Ann Rheum Dis. 2013 Jun;72(6):1053-8. doi: 10.1136/annrheumdis-2012-202160. Epub 2012 Oct 19.

PMID:
23087180
10.

Humanised mice have functional human neutrophils.

Coughlan AM, Freeley SJ, Robson MG.

J Immunol Methods. 2012 Nov 30;385(1-2):96-104. doi: 10.1016/j.jim.2012.08.005. Epub 2012 Aug 14.

PMID:
22917930
11.

Animal models of anti-neutrophil cytoplasmic antibody-associated vasculitis.

Coughlan AM, Freeley SJ, Robson MG.

Clin Exp Immunol. 2012 Sep;169(3):229-37. doi: 10.1111/j.1365-2249.2012.04616.x. Review.

12.

Transferred antigen-specific T(H)17 but not T(H)1 cells induce crescentic glomerulonephritis in mice.

Tulone C, Giorgini A, Freeley S, Coughlan A, Robson MG.

Am J Pathol. 2011 Dec;179(6):2683-90. doi: 10.1016/j.ajpath.2011.08.017. Epub 2011 Oct 8.

13.

Plasmapheresis as rescue therapy for systemic lupus erthyematosus-associated diffuse alveolar haemorrhage.

Claridge S, Das P, Dorling A, Robson MG.

BMJ Case Rep. 2011 Mar 15;2011. pii: bcr0220113893. doi: 10.1136/bcr.02.2011.3893. Erratum in: BMJ Case Rep. 2012;2012. doi:10.1136/bcr.02.2011.3893.corr1. Robson, Michael [corrected to Robson, Michael G].

14.

Toll-like receptor 4 stimulation triggers crescentic glomerulonephritis by multiple mechanisms including a direct effect on renal cells.

Giorgini A, Brown HJ, Sacks SH, Robson MG.

Am J Pathol. 2010 Aug;177(2):644-53. doi: 10.2353/ajpath.2010.091279. Epub 2010 Jun 21.

15.

Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies.

Giorgini A, Brown HJ, Lock HR, Nimmerjahn F, Ravetch JV, Verbeek JS, Sacks SH, Robson MG.

J Immunol. 2008 Dec 15;181(12):8745-52.

16.

Toll-like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibody-mediated glomerulonephritis via CXCL1 and CXCL2.

Brown HJ, Lock HR, Wolfs TG, Buurman WA, Sacks SH, Robson MG.

J Am Soc Nephrol. 2007 Jun;18(6):1732-9. Epub 2007 Apr 25.

17.

Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production.

Lock HR, Sacks SH, Robson MG.

Am J Physiol Renal Physiol. 2007 Jan;292(1):F76-81. Epub 2006 Aug 8.

18.

TLR2 stimulation of intrinsic renal cells in the induction of immune-mediated glomerulonephritis.

Brown HJ, Lock HR, Sacks SH, Robson MG.

J Immunol. 2006 Aug 1;177(3):1925-31. Erratum in: J Immunol. 2007 Jun 1;178(11):7485.

19.

Toll-like receptor 2 agonists exacerbate accelerated nephrotoxic nephritis.

Brown HJ, Sacks SH, Robson MG.

J Am Soc Nephrol. 2006 Jul;17(7):1931-9. Epub 2006 May 31.

20.

RNA interference--a new experimental and therapeutic tool.

Robson MG, Sacks SH.

Curr Opin Nephrol Hypertens. 2005 Nov;14(6):558-60. No abstract available.

PMID:
16205475

Supplemental Content

Loading ...
Support Center